Benutzer: Gast  Login
Dokumenttyp:
Randomized Controlled Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
Autor(en):
Ohlmann, Carsten-Henning; Jäschke, Michelle; Jaehnig, Peter; Krege, Susanne; Gschwend, Jürgen; Rexer, Heidrun; Junker, Kerstin; Zillmann, Roger; Rüssel, Christoph; Hellmis, Eva; Suttmann, Henrik; Janssen, Martin; Marin, Jan; Hübner, Andreas; Mathers, Michael; Gleißner, Jochen; Scheffler, Michael; Feyerabend, Susan; Telle, Jens; Klier, Jörg; Stöckle, Michael
Titel:
LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial.
Abstract:
BACKGROUND: Although the benefit of androgen deprivation therapy (ADT) continuation in metastatic castration-resistant prostate cancer (mCRPC) remains controversial, clinical evidence is lacking. Recent results indicated that treatment with abiraterone acetate (AA) plus prednisone (P) further suppresses serum testosterone levels over ADT alone, suggesting that continuation of ADT in the treatment of mCRPC may not be necessary. METHODS: In this exploratory phase 2 study, mCRPC patients were rando...     »
Zeitschriftentitel:
Prostate Cancer Prostatic Dis
Jahr:
2022
Band / Volume:
25
Heft / Issue:
4
Seitenangaben Beitrag:
778-784
Volltext / DOI:
doi:10.1038/s41391-022-00533-6
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/35430584
Print-ISSN:
1365-7852
TUM Einrichtung:
Klinik und Poliklinik für Urologie
 BibTeX